DAWN
Day One
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
DAWN Profile
Day One Biopharmaceuticals, Inc.
A clinical-stage biopharmaceutical company that develops therapies & immno-oncology for cancers
2000 Sierra Point Parkway, Suite 501, Brisbane, CA 94005
--
Day One Biopharmaceuticals, Inc., was incorporated in Delaware in November 2018 as Hero Therapeutics Holding Company, LLC. Subsequently, the Company changed its name to Day One Therapeutics Holding Company, LLC in December 2018 and to Day One Biopharmaceuticals Holding Company, LLC in March 2020. The Company has two subsidiaries: Day One Biopharmaceuticals, Inc. (formerly known as Hero Therapeutics Inc.), a wholly-owned subsidiary incorporated in Delaware in November 2018, and DOT Therapeutics, Inc., a majority subsidiary incorporated in Delaware in December 2019. They are clinical-stage biopharmaceutical companies that develop and commercialize patient-targeted therapies for all age groups with genetically defined cancers. The company's lead product candidate, DAY101, is an oral, highly selective type II pan-RAF kinase inhibitor with brain permeability.